0.00Open0.00Pre Close0 Volume0 Open Interest3.50Strike Price0.00Turnover298.90%IV-46.44%PremiumAug 16, 2024Expiry Date1.11Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.5326Delta0.2105Gamma1.54Leverage Ratio-0.0145Theta-0.0017Rho-0.82Eff Leverage0.0025Vega
Esperion Therapeutics Stock Discussion
New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries
Esperion (NASDAQ: ESPR) has launched a new digital marketing campaign called 'Lipid Lurkers' to educate patients about the risks of uncontrolled LDL cholesterol. The campaign uses animated characters to visually represent the unseen risk lurking in patients' artery walls. This initiative follows the recent FDA-app...
Esperion, a well-known entity in the biopharmaceutical industry trading under the Nasdaq symbol ESPR, has recently entered into a pivotal financial transaction with OMERS Life Sciences, a prominent investor in the life sciences sector. The essence of this transaction r...
What has Wall Street been buzzing about this week? Here are the top 5 Buy calls and the top 5 Sell calls made by Wall Street's best analysts during the week of June 17-21.
Top 5 Buy Calls:
1. Skyworks upgraded to Buy at B. Riley
$Skyworks Solutions(SWKS.US)$
B. Riley upgraded Skyworks (SWKS) to Buy from Neutral with a price target of $130, up from $96, ahead of the July 8 through 11 SEM...
No comment yet